Rheumatoid Arthritis Treatment With SIMPONI ARIA® (golimumab)

FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE RA, IN COMBINATION WITH MTX

SIMPONI ARIA^® is ready to fight the symptoms of moderately to severely active RA.

PATIENT-REPORTED OUTCOMES (PROs)

Learn more about the SIMPONI ARIA^® PRO data for HAQ-DI, SF-36, and FACIT-F in a clinical trial.

SEE RESULTS

DOSING CALCULATOR

Calculate an adult patient's dose of SIMPONI ARIA^® based on weight.

GET STARTED

ACCESS AND AFFORDABILITY

View first-line coverage rates for SIMPONI ARIA^®.

LEARN MORE

cp-44006v5

This site is published by Janssen Biotech, Inc., which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. Janssen Biotech, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

cp-44006v5

Third party trademarks used herein are trademarks of their respective owners.

FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE RA, IN COMBINATION WITH MTX

ABOUT SIMPONI ARIA^®

DEMONSTRATED EFFICACY

PATIENT-REPORTED OUTCOMES (PROs)

DOSING CALCULATOR

ACCESS AND AFFORDABILITY

You are leaving this website

FOR ADULTS WITH MODERATELY TO SEVERELY ACTIVE RA, IN COMBINATION WITH MTX

ABOUT SIMPONI ARIA®

DEMONSTRATED EFFICACY

PATIENT-REPORTED OUTCOMES (PROs)

DOSING CALCULATOR

ACCESS AND AFFORDABILITY

You are leaving this website

ABOUT SIMPONI ARIA^®